Literature DB >> 1772999

Thrombin structure and function: why thrombin is the primary target for antithrombotics.

J W Fenton1, F A Ofosu, D G Moon, J M Maraganore.   

Abstract

Thrombin has both beneficial and harmful effects. In order of importance, at very low concentrations, alpha-thrombin firstly amplifies its own generation through the activation of factors V and VIII, which are the primary targets of antithrombotic agents. It secondly functions at the cellular level where, at low concentrations it activates platelets, and at higher concentrations, induces endothelial cell changes (e.g., shape changes, albumin transport release of plasminogen activators and other substances). It thirdly converts fibrinogen into clottable fibrin and becomes actively incorporated into the forming thrombus. In addition, it activates protein C, which in turn degrades factors V and VIII (and/or their activated forms) and causes the shutdown of thrombin generation. When compared to other serine proteinases of the blood coagulation and fibrinolytic systems, alpha-thrombin is unique in that it loses most of its proenzyme activation fragment and has developed multisite short-ranged bridge-binding interactions, which appear to explain thrombin specificity. To understand thrombin is to understand haemostasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772999

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  21 in total

1.  Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.

Authors:  E Gandossi; C Lunven; C N Berry
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.

Authors:  L Ma; S N Elliott; G Cirino; A Buret; L J Ignarro; J L Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human alpha-thrombin.

Authors:  Emilia L Wu; Ye Mei; KeLi Han; John Z H Zhang
Journal:  Biophys J       Date:  2007-03-23       Impact factor: 4.033

4.  Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.

Authors:  G De Simone; A Lombardi; S Galdiero; F Nastri; R Della Morte; N Staiano; C Pedone; M Bolognesi; V Pavone
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

5.  Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug.

Authors:  P Fuentes-Prior; C Noeske-Jungblut; P Donner; W D Schleuning; R Huber; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Depletion of plasma albumin for proteomic analysis of Bothrops jararaca snake plasma.

Authors:  Karen de Morais-Zani; Kathleen Fernandes Grego; Aparecida Sadae Tanaka; Anita Mitico Tanaka-Azevedo
Journal:  J Biomol Tech       Date:  2011-07

Review 7.  Thrombin inhibitors from different animals.

Authors:  A M Tanaka-Azevedo; K Morais-Zani; R J S Torquato; A S Tanaka
Journal:  J Biomed Biotechnol       Date:  2010-10-04

8.  Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate.

Authors:  E Pipili-Synetos; A Papageorgiou; E Sakkoula; G Sotiropoulou; T Fotsis; G Karakiulakis; M E Maragoudakis
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position.

Authors:  G Claeson; M Philipp; E Agner; M F Scully; R Metternich; V V Kakkar; T DeSoyza; L H Niu
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

10.  High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains.

Authors:  H R Gralnick; S Williams; L P McKeown; K Hansmann; J W Fenton; H Krutzsch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.